Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation on microRNA (miRNA) expression patterns. Interestingly, we discover that miRNAs capable of inhibiting key members of activated pathways are frequently diminished. Building on this observation, we develop an approach that integrates a low-miRNA-expression signature to identify druggable target genes in cancer. We train and validate our approach in colorectal cancer cells and extend it to diverse cancer models using patient-derived in vitro and in vivo systems. Finally, we demonstrate its additional value to support genomic and transcriptomic-based drug prediction strategies in a pan-cancer patient cohort from the National Center for Tumor Diseases (NCT)/German Cancer Consortium (DKTK) Molecularly Aided Stratification for Tumor Eradication (MASTER) precision oncology trial. In conclusion, our strategy can predict cancer vulnerabilities with high sensitivity and accuracy and might be suitable for future therapy recommendations in a variety of cancer subtypes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 4(2023), 10 vom: 17. Okt., Seite 101200 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wurm, Alexander A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer driver |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 13.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2023.101200 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362309884 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362309884 | ||
| 003 | DE-627 | ||
| 005 | 20231226090953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2023.101200 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362309884 | ||
| 035 | |a (NLM)37734378 | ||
| 035 | |a (PII)S2666-3791(23)00367-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wurm, Alexander A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation on microRNA (miRNA) expression patterns. Interestingly, we discover that miRNAs capable of inhibiting key members of activated pathways are frequently diminished. Building on this observation, we develop an approach that integrates a low-miRNA-expression signature to identify druggable target genes in cancer. We train and validate our approach in colorectal cancer cells and extend it to diverse cancer models using patient-derived in vitro and in vivo systems. Finally, we demonstrate its additional value to support genomic and transcriptomic-based drug prediction strategies in a pan-cancer patient cohort from the National Center for Tumor Diseases (NCT)/German Cancer Consortium (DKTK) Molecularly Aided Stratification for Tumor Eradication (MASTER) precision oncology trial. In conclusion, our strategy can predict cancer vulnerabilities with high sensitivity and accuracy and might be suitable for future therapy recommendations in a variety of cancer subtypes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a cancer driver | |
| 650 | 4 | |a drug response | |
| 650 | 4 | |a miRNA signatures | |
| 650 | 4 | |a organoids | |
| 650 | 4 | |a precision oncology | |
| 650 | 4 | |a spheroids | |
| 650 | 4 | |a target prediction | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Brilloff, Silke |e verfasserin |4 aut | |
| 700 | 1 | |a Kolovich, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Rahimian, Elahe |e verfasserin |4 aut | |
| 700 | 1 | |a Kufrin, Vida |e verfasserin |4 aut | |
| 700 | 1 | |a Bill, Marius |e verfasserin |4 aut | |
| 700 | 1 | |a Carrero, Zunamys I |e verfasserin |4 aut | |
| 700 | 1 | |a Drukewitz, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Krüger, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Hüther, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Uhrig, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Oster, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Westphal, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Meier, Friedegund |e verfasserin |4 aut | |
| 700 | 1 | |a Pfütze, Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a Hübschmann, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Horak, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kreutzfeldt, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Schröck, Evelin |e verfasserin |4 aut | |
| 700 | 1 | |a Baretton, Gustavo |e verfasserin |4 aut | |
| 700 | 1 | |a Heining, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Möhrmann, Lino |e verfasserin |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Ball, Claudia R |e verfasserin |4 aut | |
| 700 | 1 | |a Glimm, Hanno |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 4(2023), 10 vom: 17. Okt., Seite 101200 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:10 |g day:17 |g month:10 |g pages:101200 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2023.101200 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 10 |b 17 |c 10 |h 101200 | ||